HRTX RSI Chart
Last 7 days
15.5%
Last 30 days
15.5%
Last 90 days
11.5%
Trailing 12 Months
166.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 132.1M | 0 | 0 | 0 |
2023 | 113.8M | 118.0M | 122.8M | 127.0M |
2022 | 89.8M | 95.0M | 98.3M | 107.7M |
2021 | 83.3M | 83.0M | 86.3M | 86.3M |
2020 | 139.8M | 125.8M | 103.1M | 88.6M |
2019 | 97.5M | 116.9M | 139.7M | 146.0M |
2018 | 38.7M | 47.5M | 58.7M | 77.5M |
2017 | 4.9M | 13.4M | 22.0M | 30.8M |
2016 | 0 | 0 | 0 | 1.5M |
2011 | 1.5M | 1.2M | 825.0K | 646.0K |
2010 | 0 | 1.3M | 1.3M | 1.3M |
2009 | 0 | 0 | 0 | 1.3M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 19, 2024 | forbes william p | acquired | - | - | 3,874 | evp, chief development officer |
Apr 19, 2024 | duarte ira | acquired | - | - | 3,874 | evp, chief financial officer |
Apr 19, 2024 | duarte ira | sold (taxes) | -2,962 | 2.64 | -1,122 | evp, chief financial officer |
Apr 19, 2024 | collard craig a | acquired | - | - | 13,797 | chief executive officer |
Apr 03, 2024 | collard craig a | acquired | - | - | 62,500 | chief executive officer |
Jan 19, 2024 | johnson craig a | acquired | - | - | 13,948 | - |
Jan 19, 2024 | christian waage | acquired | - | - | 13,948 | - |
Jan 19, 2024 | rodriguez susan | acquired | - | - | 13,948 | - |
Jan 19, 2024 | dissanaike sharmila | acquired | - | - | 13,948 | - |
Jan 19, 2024 | morgan adam | acquired | - | - | 13,948 | - |
Which funds bought or sold HRTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | B. Riley Wealth Advisors, Inc. | sold off | -100 | -19,533 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 61.15 | 460,429 | 743,642 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.93 | -140 | 28,833 | -% |
May 16, 2024 | COMERICA BANK | reduced | -20.96 | 172 | 772 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 26.04 | 334,053 | 651,066 | -% |
May 15, 2024 | Capital Planning Advisors, LLC | added | 60.88 | 109,342 | 176,781 | 0.03% |
May 15, 2024 | Engineers Gate Manager LP | added | 9.82 | 91,820 | 208,132 | -% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | unchanged | - | 1,979,500 | 5,124,500 | 0.53% |
May 15, 2024 | CAROLINAS WEALTH CONSULTING LLC | new | - | 54,569 | 54,569 | 0.01% |
May 15, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 15.39 | 38,000 | 83,000 | -% |
Unveiling Heron Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Heron Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Heron Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 1.3% | 34,670 | 34,233 | 31,434 | 31,762 | 29,615 | 30,028 | 26,557 | 27,630 | 23,457 | 20,655 | 23,230 | 22,443 | 20,018 | 20,605 | 19,965 | 22,668 | 25,400 | 35,083 | 42,624 | 36,659 | 31,602 |
Gross Profit | 7.7% | 26,226 | 24,348 | 13,226 | - | 12,761 | - | 11,840 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Costs and Expenses | 93.2% | 31,024 | 16,062 | 38,155 | 74,165 | 62,678 | 23,991 | 53,722 | 77,128 | 86,380 | 74,192 | 74,938 | 82,912 | 72,132 | 81,901 | 78,349 | 78,417 | 78,134 | 94,445 | 77,477 | 88,438 | 96,302 |
Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96,302 |
S&GA Expenses | -7.2% | 11,442 | 12,328 | 12,956 | 21,205 | 21,154 | 17,775 | 18,378 | 22,938 | 23,422 | 24,487 | 25,206 | 22,250 | 15,236 | 15,553 | 12,515 | 15,589 | 20,196 | 20,420 | 16,977 | 23,647 | 28,720 |
R&D Expenses | -57.9% | 4,608 | 10,950 | 13,558 | 17,572 | 13,817 | 11,057 | 25,545 | 28,834 | 42,070 | 28,877 | 28,595 | 35,233 | 38,116 | 44,453 | 49,182 | 44,004 | 36,894 | 48,277 | 34,708 | 41,425 | 42,972 |
EBITDA Margin | 3.2% | -0.04* | -0.04* | -0.05* | -0.05* | -0.05* | -0.06* | -0.06* | -0.06* | -0.07* | -0.07* | -0.08* | -0.08* | - | - | - | - | - | - | - | - | - |
Interest Expenses | -74.8% | 649 | 2,580 | 163 | - | - | 1,349 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | 3.8% | -0.09* | -0.09* | -0.09* | -0.10* | -0.10* | -0.11* | -0.12* | -0.12* | -0.13* | -0.13* | -0.13* | -0.14* | - | - | - | - | - | - | - | - | - |
Net Income | 70.5% | -3,160 | -10,724 | -25,008 | -42,059 | -32,768 | -19,869 | -41,908 | -56,359 | -63,888 | -54,646 | -52,408 | -61,015 | -52,614 | -62,281 | -58,228 | -55,190 | -51,579 | -57,920 | -33,595 | -50,222 | -63,012 |
Net Income Margin | 29.6% | -0.61* | -0.87* | -0.97* | -1.16* | -1.33* | -1.69* | -2.21* | -2.39* | -2.58* | -2.56* | -2.65* | -2.82* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -542.9% | -9,766 | 2,205 | -9,972 | -27,443 | -25,124 | -37,948 | -37,111 | -28,695 | -44,983 | -45,648 | -54,697 | -63,307 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -2.1% | 218 | 223 | 229 | 201 | 221 | 251 | 272 | 244 | 274 | 306 | 352 | 404 | 311 | 354 | 390 | 433 | 479 | 513 | 393 | 412 | 436 |
Current Assets | -1.5% | 186 | 189 | 194 | 165 | 178 | 205 | 224 | 194 | 223 | 254 | 315 | 367 | 272 | 314 | 351 | 393 | 438 | 479 | 364 | 381 | 406 |
Cash Equivalents | -28.7% | 20.00 | 29.00 | 35.00 | 13.00 | 27.00 | 15.00 | 50.00 | 49.00 | 57.00 | 91.00 | 160 | 191 | 60.00 | 105 | 95.00 | 81.00 | 103 | 72.00 | 60.00 | 53.00 | 23.00 |
Inventory | 0.9% | 42.00 | 42.00 | 42.00 | 45.00 | 52.00 | 55.00 | 52.00 | 61.00 | 56.00 | 48.00 | 42.00 | 43.00 | 43.00 | 42.00 | 43.00 | 41.00 | 35.00 | 25.00 | 24.00 | 29.00 | 31.00 |
Net PPE | -4.3% | 19.00 | 20.00 | 21.00 | 21.00 | 22.00 | 22.00 | 23.00 | 23.00 | 24.00 | 24.00 | 23.00 | 22.00 | 23.00 | 23.00 | 22.00 | 22.00 | 22.00 | 20.00 | 16.00 | 18.00 | 16.00 |
Liabilities | -1.9% | 252 | 256 | 257 | 241 | 232 | 237 | 250 | 266 | 250 | 228 | 234 | 244 | 115 | 117 | 113 | 109 | 113 | 109 | 108 | 106 | 104 |
Current Liabilities | -5.4% | 75.00 | 80.00 | 80.00 | 87.00 | 78.00 | 82.00 | 94.00 | 109 | 93.00 | 71.00 | 72.00 | 82.00 | 101 | 103 | 98.00 | 93.00 | 97.00 | 97.00 | 97.00 | 95.00 | 92.00 |
Shareholder's Equity | 0.6% | -33.77 | -33.97 | - | - | -11.43 | 14.00 | 22.00 | - | 24.00 | 78.00 | 119 | 160 | 196 | 236 | 277 | 324 | 365 | 404 | 285 | 305 | 332 |
Retained Earnings | -0.2% | -1,909 | -1,906 | -1,895 | -1,870 | -1,800 | -1,795 | -1,775 | -1,733 | -1,677 | -1,613 | -1,558 | -1,506 | -1,445 | -1,392 | -1,330 | -1,272 | -1,217 | -1,165 | -1,107 | -1,073 | -1,023 |
Additional Paid-In Capital | 0.2% | 1,874 | 1,871 | 1,866 | 1,830 | 1,816 | 1,808 | 1,797 | 1,711 | 1,700 | 1,690 | 1,677 | 1,665 | 1,641 | 1,628 | 1,606 | 1,594 | 1,581 | 1,568 | 1,392 | 1,378 | 1,355 |
Accumulated Depreciation | -100.0% | - | 17.00 | - | - | - | 14.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding | -100.0% | - | 150 | 145 | 119 | 119 | 119 | 112 | 102 | 102 | 102 | 97.00 | 95.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 120 | - | - | - | 285 | - | - | - | 1,600 | - | - | - | 1,300 | - | - | - | 1,400 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -487.6% | -9,516 | 2,455 | -9,179 | -27,165 | -24,900 | -37,534 | -37,066 | -28,373 | -43,939 | -45,258 | -53,166 | -62,992 | -41,938 | -52,554 | -42,054 | -57,277 | -32,935 | -26,977 | -25,471 | -23,108 | -49,024 |
Share Based Compensation | -21.9% | 3,375 | 4,324 | 6,683 | 13,900 | 7,947 | 10,514 | 11,198 | 10,353 | 10,915 | 12,888 | 11,236 | 11,241 | 11,486 | 16,035 | 11,095 | 11,114 | 11,974 | 11,099 | 9,704 | 12,706 | 17,902 |
Cashflow From Investing | 114.5% | 1,278 | -8,836 | -23,221 | 13,218 | 36,834 | 2,021 | -36,047 | 19,756 | 10,946 | -24,258 | 21,634 | 39,697 | -4,344 | 56,789 | 55,943 | 32,408 | 63,815 | -126,359 | 28,627 | 41,839 | 34,110 |
Cashflow From Financing | -94.5% | 11.00 | 199 | 53,797 | 319 | -208 | 439 | 74,942 | 315 | -637 | 487 | -71.00 | 154,729 | 883 | 5,762 | 524 | 2,312 | 507 | 165,126 | 3,914 | 10,846 | 6,539 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenues: | ||
Net product sales | $ 34,670 | $ 29,615 |
Cost of product sales | 8,444 | 16,854 |
Gross profit | 26,226 | 12,761 |
Operating expenses: | ||
Research and development | 4,608 | 8,836 |
General and administrative | 14,974 | 15,834 |
Sales and marketing | 11,442 | 21,154 |
Total operating expenses | 31,024 | 45,824 |
Loss from operations | (4,798) | (33,063) |
Other income, net | 1,638 | 295 |
Net loss | (3,160) | (32,768) |
Other comprehensive loss: | ||
Unrealized (losses) gains on short-term investments | (19) | 28 |
Comprehensive loss | $ (3,179) | $ (32,740) |
Basic net loss per share | $ (0.02) | $ (0.27) |
Weighted average common shares outstanding, basic | 151,199 | 119,246 |
Diluted net loss per share | $ (0.02) | $ (0.27) |
Weighted average common shares outstanding, diluted | 151,199 | 119,246 |
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 20,450 | $ 28,677 |
Short-term investments | 51,074 | 51,732 |
Accounts receivable, net | 65,322 | 60,137 |
Inventory | 42,473 | 42,110 |
Prepaid expenses and other current assets | 6,584 | 6,118 |
Total current assets | 185,903 | 188,774 |
Property and equipment, net | 19,306 | 20,166 |
Right-of-use lease assets | 4,794 | 5,438 |
Other assets | 7,884 | 8,128 |
Total assets | 217,887 | 222,506 |
Current liabilities: | ||
Accounts payable | 837 | 3,240 |
Accrued clinical and manufacturing liabilities | 19,943 | 22,291 |
Accrued payroll and employee liabilities | 7,647 | 9,224 |
Other accrued liabilities | 43,814 | 41,855 |
Current lease liabilities | 3,137 | 3,075 |
Total current liabilities | 75,378 | 79,685 |
Non-current lease liabilities | 2,045 | 2,800 |
Non-current notes payable, net | 24,447 | 24,263 |
Non-current convertible notes payable, net | 149,542 | 149,490 |
Other non-current liabilities | 241 | 241 |
Total liabilities | 251,653 | 256,479 |
Stockholders' deficit: | ||
Common stock | 1,504 | 1,503 |
Additional paid-in capital | 1,873,910 | 1,870,525 |
Accumulated other comprehensive (loss)/income | (6) | 13 |
Accumulated deficit | (1,909,174) | (1,906,014) |
Total stockholders' deficit | (33,766) | (33,973) |
Total liabilities and stockholders' deficit | $ 217,887 | $ 222,506 |